within Pharmacolibrary.Drugs.S_SensoryOrgans.S01C_AntiinflammatoryAgentsAndAntiinfectivesInCombina.S01CB01_Dexamethasone;

model Dexamethasone_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 9.944444444444446e-07,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0028333333333333335,
    Tlag = 600,
    Vdp = 0.0092,
    k12 = 2.027777777777778e-06,
    k21 = 2.027777777777778e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dexamethasone_1</td></tr><tr><td>ATC code:</td><td>S01CB01_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.58</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant properties. It is commonly used in the treatment of a variety of conditions, including allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, and respiratory disorders. It is approved and widely used today in both oral and parenteral formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from oral administration in healthy adults.</p><h4>References</h4><ol><li><p>Wen, J, et al., &amp; Gonzalez, D (2024). Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity. <i>Journal of clinical pharmacology</i> 64(12) 1491–1504. DOI:<a href=\"https://doi.org/10.1002/jcph.6108\">10.1002/jcph.6108</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39120865/\">https://pubmed.ncbi.nlm.nih.gov/39120865</a></p></li><li><p>Wang, X, et al., &amp; Kansra, V (2019). Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting. <i>Clinical pharmacology in drug development</i> 8(7) 850–860. DOI:<a href=\"https://doi.org/10.1002/cpdd.733\">10.1002/cpdd.733</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31418538/\">https://pubmed.ncbi.nlm.nih.gov/31418538</a></p></li><li><p>Nakade, S, et al., &amp; Miyata, Y (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. <i>Cancer chemotherapy and pharmacology</i> 63(1) 75–83. DOI:<a href=\"https://doi.org/10.1007/s00280-008-0713-y\">10.1007/s00280-008-0713-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18317761/\">https://pubmed.ncbi.nlm.nih.gov/18317761</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01CB01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dexamethasone_1;
